Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma
- PMID: 20061986
- DOI: 10.1097/CMR.0b013e328335a916
Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma
Abstract
This study evaluated the expression profile of hepatocyte growth factor (HGF), c-Met, epidermal growth factor receptor (EGFR), insulin-like growth factor-1 receptor (IGF-1R), and vitreal and serum EGF, HGF, IGF-1 levels in patients with uveal melanoma and assessed their correlation with the clinicopathological parameters. Forty patients with uveal melanoma were included in the study. Clinicopathological parameters were evaluated with hematoxylin-eosin staining. HGF, c-Met, EGFR, and IGF-1R expressions were evaluated immunohistochemically. HGF, EGF, and IGF-1 levels were measured with enzyme-linked immunosorbent assay in vitreous and serum specimens taken at enucleation and 6 months after the enucleation. HGF, c-Met, IGF-1R, and EGFR expressions were detected in 57.5, 20, 20, and 12.5% of cases, respectively. IGF-1R expression was significantly correlated with the degree of pigmentation, necrosis, and lymphocyte infiltration (P=0.013, 0.04, and 0.017). EGFR expression was significantly correlated with the mitosis rate (P=0.02). Vitreal EGF and serum IGF-1 levels were significantly higher in patients with scleral invasion (15.72+/-29.13, 199.01+/-154.01 pg/ml, respectively) when compared with the patients without invasion (0.56+/-1.05, 33.01+/-36.52 pg/ml) (P=0.03 and 0.015). When the preoperative and postoperative serum growth factor levels were compared, the serum EGF level was found to be lower (125.93+/-62.84, 100.02+/-31.19 pg/ml, P=0.007) and the serum IGF-1 level (165.81+/-153.6, 301.35+/-131.24 pg/ml, P<0.001) was found to be higher in the postoperative 6-month specimens. Uveal melanomas express HGF, c-Met, EGFR, and IGF-1R. Vitreal growth factor levels and expression of EGFR and IGF-1R are correlated with some clinicopathological parameters. IGF-1 and EGF may have a role in the development and progression of uveal melanoma.
Similar articles
-
Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications.Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4372-5. doi: 10.1167/iovs.05-0322. Invest Ophthalmol Vis Sci. 2005. PMID: 16303922
-
Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications.Acta Ophthalmol. 2008 Nov;86 Thesis 4:20-5. doi: 10.1111/j.1755-3768.2008.01182.x. Acta Ophthalmol. 2008. PMID: 19032678
-
Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study.Curr Eye Res. 2007 Mar;32(3):281-90. doi: 10.1080/02713680601161220. Curr Eye Res. 2007. PMID: 17453948
-
HGF/c-MET Signaling in Melanocytes and Melanoma.Int J Mol Sci. 2018 Dec 3;19(12):3844. doi: 10.3390/ijms19123844. Int J Mol Sci. 2018. PMID: 30513872 Free PMC article. Review.
-
Clinical, pathologic, and imaging features and biological markers of uveal melanoma.Methods Mol Biol. 2014;1102:397-425. doi: 10.1007/978-1-62703-727-3_21. Methods Mol Biol. 2014. PMID: 24258990 Review.
Cited by
-
Exploring recent advances in signaling pathways and hallmarks of uveal melanoma: a comprehensive review.Explor Target Antitumor Ther. 2025 Apr 2;6:1002306. doi: 10.37349/etat.2025.1002306. eCollection 2025. Explor Target Antitumor Ther. 2025. PMID: 40177537 Free PMC article. Review.
-
Targeting IRS-1/2 in Uveal Melanoma Inhibits In Vitro Cell Growth, Survival and Migration, and In Vivo Tumor Growth.Cancers (Basel). 2022 Dec 19;14(24):6247. doi: 10.3390/cancers14246247. Cancers (Basel). 2022. PMID: 36551732 Free PMC article.
-
Insulin-like growth factor system and sporadic malignant melanoma.Am J Pathol. 2011 Jan;178(1):26-31. doi: 10.1016/j.ajpath.2010.11.004. Epub 2010 Dec 23. Am J Pathol. 2011. PMID: 21224039 Free PMC article. Review.
-
Prognostic value of receptor tyrosine kinases in malignant melanoma patients: A systematic review and meta-analysis of immunohistochemistry.Front Oncol. 2022 Sep 23;12:819051. doi: 10.3389/fonc.2022.819051. eCollection 2022. Front Oncol. 2022. PMID: 36212475 Free PMC article.
-
MET: a promising anticancer therapeutic target.Nat Rev Clin Oncol. 2012 May 8;9(6):314-26. doi: 10.1038/nrclinonc.2012.71. Nat Rev Clin Oncol. 2012. PMID: 22566105 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous